PharmGKB ID	Variant	Literature	Genes	Association	Significance	P-Value	# of Cases	# of Controls	Biogeographical Groups	Phenotype Categories	Pediatric	More Details	Drugs
1446898364	rs489693	PMID:23920449	MC4R	Genotype AA is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes AC + CC.	yes	= 0.017	86		Unknown	Other	false	The authors analyzed the whole population of all patients administered one of many anti-psychotics, then a subpopulation without additional weight gain-inducing co-medication (adjusted sub-population)(weight-gaining co-meds included TCA, mirtazapine, lithium, valproic acid, and paroxetine) as well as a sub-group of patients for whom anti-psychotics were given for a first episode.The authors calculated adjusted means for weight gain 4 wk post-initiation of medication using ANCOVA and rs489693 genotype as a independent variable. Patients with the AA genotype had between 2.2–3.1 higher increase in weight gain vs. patients with the CC genotype.	amisulpride; clozapine; olanzapine; paliperidone; quetiapine; risperidone
1448998876	rs3813928	PMID:20504252	HTR2C	Genotype GG is associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AA + AG.	yes	= 0.038	62	66	European	Toxicity	false	Groups compared were GG females plus G males vs AG females + AA females + A males. (gene is x-linked).	amisulpride; clozapine; olanzapine; quetiapine; risperidone
1448639707	rs7412	PMCID:PMC5600660	APOE	Allele C is not associated with Memory Disorders when exposed to aripiprazole, clozapine, olanzapine, quetiapine, risperidone or ziprasidone in people with Psychotic Disorders, schizoaffective disorder and Schizophrenia as compared to allele T.	no	> 0.05	122		Unknown	Other	false	Verbal memory and exploratory recall ratio performance analysis were significantly influenced by genetics BUT only in the low-education group. However, medication use (ACEI or ARB interacted with RAS risk alleles, statin interacted with APOE e 4 carrier status, or atypical vs typical antipsychotic use) was not associated with outcomes.	aripiprazole; clozapine; olanzapine; quetiapine; risperidone; ziprasidone
1183629449	rs1800497	PMID:23859574	ANKK1	Genotype AA is associated with increased risk of Headache when treated with olanzapine, quetiapine or risperidone in healthy individuals as compared to genotype GG.	yes	= 0.035	161		European	Toxicity	false	A higher frequency of individuals with headache were found to have the DRD2 A1/A1 (30%) genotype vs A2/A2 (9%). Those with the A1/A2 genotype were in between (20%). Here allele A is used to represent A1 which is less frequent in Caucasian populations and G to represent A2 which is the major allele in Caucasians.  P value <0.05 for Chi-Squared analysis for this association. Statistics given below are for multivariate analysis for factors contributing to headache.	olanzapine; quetiapine; risperidone
1449181797	rs518147	PMID:29441581	HTR2C	Genotype CC is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine, quetiapine or risperidone in people with Psychotic Disorders or Schizophrenia as compared to genotypes CG + GG.	yes	= 0.048	64	136	East Asian	Toxicity	false	Most patients were on mono therapy (94%) risperidone or clozapine, 6% were on 2 drugs.	clozapine; olanzapine; quetiapine; risperidone
1451147640	CYP3A4*1; CYP3A4*3; CYP3A4*20; CYP3A4*22	PMCID:PMC7235792	CYP3A4	CYP3A4 *3 + *20 + *22 are associated with increased exposure to fentanyl, imatinib or quetiapine in healthy individuals as compared to CYP3A4 *1.	not stated		251		Multiple groups, Caucasian, Latin-American, Black and Arab subjects	Metabolism/PK	false	AUC of all three drugs was increased in the presence of CYP3A4 variants. Statistical analysis was not carried out for individual drugs due to the low number of subjects carrying CYP3A4 variants. *3 allele was identified using rs4986910, *20 was identified using rs67666821 and *22 was identified using rs35599367.	fentanyl; imatinib; quetiapine
1447520463	CYP1A2*1A; CYP1A2*1C; CYP1A2*1F	PMID:25025989	CYP1A2	CYP1A2 *1A/*1C + *1C/*1F is associated with increased exposure to quetiapine in healthy individuals as compared to CYP1A2 *1A/*1A + *1F/*1F.	yes	= 0.026	79		European	Metabolism/PK	false		quetiapine
1451550220	rs362719	PMCID:PMC7005197	RELN	Allele A is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele C.	no	= 0.732	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1448639698	rs429358	PMCID:PMC5600660	APOE	Allele C is not associated with Memory Disorders when exposed to aripiprazole, clozapine, olanzapine, quetiapine, risperidone or ziprasidone in people with Psychotic Disorders, schizoaffective disorder and Schizophrenia as compared to allele T.	no	> 0.05	122		Unknown	Other	false	Verbal memory and exploratory recall ratio performance analysis were significantly influenced by genetics BUT only in the low-education group. However, medication use (ACEI or ARB interacted with RAS risk alleles, statin interacted with APOE e 4 carrier status, or atypical vs typical antipsychotic use) was not associated with outcomes.	aripiprazole; clozapine; olanzapine; quetiapine; risperidone; ziprasidone
1448998866	rs498207	PMID:20504252	HTR2C	Genotype AA is associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AG + GG.	yes	= 0.0196	62	66	European	Toxicity	false	Groups compared were AA females plus A males vs AG females + GG females + G males. (gene is x-linked).	amisulpride; clozapine; olanzapine; quetiapine; risperidone
1447680089	rs10848635	PMID:26049408	CACNA1C	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.32	176		East Asian	Efficacy	false	Study looked at association of genotype and alleles in response to antipsychotics, using 4 PANSS scales (Positive and Negative Syndrome Scale): PANSS total, PANSS positive, PANSS negative, PANSS general. Patients were on one of the following drugs: risperidone, olanzapine, quetiapine.	olanzapine; quetiapine; risperidone
1448639689	rs699	PMCID:PMC5600660	AGT	Allele G is not associated with Memory Disorders when exposed to aripiprazole, clozapine, olanzapine, quetiapine, risperidone or ziprasidone in people with Psychotic Disorders, schizoaffective disorder and Schizophrenia as compared to allele A.	no	> 0.05	122		Unknown	Other	false	Verbal memory and exploratory recall ratio performance analysis were significantly influenced by genetics BUT only in the low-education group. However, medication use (ACEI or ARB interacted with RAS risk alleles, statin interacted with APOE e 4 carrier status, or atypical vs typical antipsychotic use) was not associated with outcomes.	aripiprazole; clozapine; olanzapine; quetiapine; risperidone; ziprasidone
655387138	rs951439	PMCID:PMC2194758	RGS4	Genotype TT is associated with increased response to quetiapine and ziprasidone in people with Schizophrenia as compared to genotype CC.	not stated		198		Unknown	Efficacy	false		quetiapine; ziprasidone
1183491224	rs2134227	PMCID:PMC3845218	SV2C	Genotype GG is not associated with response to quetiapine in people with Schizophrenia as compared to genotypes CC + CG.	no	= 0.996	124		European	Efficacy	false	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	quetiapine
1449181811	rs12836771	PMID:29441581	HTR2C; MIR1264; MIR1912	Genotype GG is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine, quetiapine or risperidone in people with Psychotic Disorders and Schizophrenia as compared to genotypes AA + AG.	yes	= 0.042	64	136	East Asian	Toxicity	false	Most patients were on mono therapy (94%) risperidone or clozapine, 6% were on 2 drugs.	clozapine; olanzapine; quetiapine; risperidone
1183491228	rs31244	PMCID:PMC3845218	SV2C	Genotype GG is not associated with response to quetiapine in people with Schizophrenia as compared to genotypes AA + AG.	no	= 0.996	124		European	Efficacy	false	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	quetiapine
1451550226	rs7341475	PMCID:PMC7005197	RELN	Allele A is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele G.	no	= 0.978	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
981475608	rs10042486	PMID:22120873	HTR1A	Genotype TT is associated with increased response to amisulpride, antipsychotics, olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to genotypes CC + CT.	yes	= 1.0E-6	221		East Asian	Efficacy	false	Response was measured by difference in PANSS scores between admission and discharge. Subjects with the TT genotype were more likely to improve on the PANSS total, positive and negative scores as compared to the CC + CT genotypes. Percentages of study participants taking each drug are as follow: risperidone (34%), olanzapine (24%), quetiapine (6%), amisulpiride (15%), and other antipsychotics (4%).	amisulpride; antipsychotics; olanzapine; quetiapine; risperidone
1447680083	rs758723	PMID:26049408	CACNA1C	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.40	176		East Asian	Efficacy	false	Study looked at association of genotype and alleles in response to antipsychotics, using 4 PANSS scales (Positive and Negative Syndrome Scale): PANSS total, PANSS positive, PANSS negative, PANSS general. Patients were on one of the following drugs: risperidone, olanzapine, quetiapine.	olanzapine; quetiapine; risperidone
1449181819	rs7799039	PMID:29441581	LEP	Genotype AA is not associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine, quetiapine or risperidone in people with Psychotic Disorders and Schizophrenia as compared to genotypes AG + GG.	no	= 0.321	64	136	East Asian	Toxicity	false	Most patients were on mono therapy (94%) risperidone or clozapine, 6% were on 2 drugs.	clozapine; olanzapine; quetiapine; risperidone
1451550232	rs39339	PMCID:PMC7005197	RELN	Allele G is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.841	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1183491220	rs10214163	PMCID:PMC3845218	SV2C	Genotype TT is not associated with response to quetiapine in people with Schizophrenia as compared to genotypes CC + CT.	no	= 0.996	124		European	Efficacy	false	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	quetiapine
1183699245	rs1045642	PMID:24240480	ABCB1	Allele A is not associated with differences pharmacokinetic parameters when treated with quetiapine in healthy individuals as compared to allele G.	no	> 0.05	40		East Asian	Metabolism/PK	false		quetiapine
1448998908	rs10490624	PMID:20504252	INSIG2	Genotype TT is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotype CT.	no	= 0.0196	62	66	European	Toxicity	false	No CC homozygotes in sample set.	amisulpride; clozapine; olanzapine; quetiapine; risperidone
1450815067	rs2164660	PMCID:PMC3922978	PDE4D	Allele A is associated with increased response to quetiapine in people with Schizophrenia as compared to allele G.	yes	= 1.87E-07	160		Multiple groups, European American, African American and 'Other' ethnicities.	Efficacy	false	The number of A alleles present in a patient was negatively associated with PGI score. Please note that this variant is in high linkage disequilibrium with rs17742120 and rs17382202.	quetiapine
1451550247	rs3808035	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele A.	no	= 0.695	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1183699240	rs2032582	PMID:24240480	ABCB1	Allele C is not associated with differences pharmacokinetic parameters when treated with quetiapine in healthy individuals as compared to allele T.	no	> 0.05	40		East Asian	Metabolism/PK	false		quetiapine
1451550241	rs3819479	PMCID:PMC7005197	RELN	Allele A is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.529	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1449189063	CYP2D6*1; CYP2D6*4; CYP2D6*41	PMCID:PMC5810290	CYP2D6	CYP2D6 *4 + *41 are associated with Binge eating disorder, Constipation, Dystonia, extrapyramidal symptoms, Galactorrhea, Psychomotor Agitation and Weight gain when treated with aripiprazole, quetiapine and risperidone in children with Schizophrenia as compared to CYP2D6 *1.	not stated		1		Unknown	Other	true		aripiprazole; quetiapine; risperidone
1183629349	rs1806201	PMID:23859574	GRIN2B	Genotype AA is associated with increased likelihood of sleepiness when treated with quetiapine in healthy individuals as compared to genotypes AG + GG.	not stated	= 0.025	79		European	Toxicity	false	Alleles have been complemented to the plus chromosomal strand. Statistics did not mention correction for multiple testing. Statistics did not mention correction for multiple testing.	quetiapine
1448998900	rs17587100	PMID:20504252	INSIG2	Genotype AA is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AC + CC.	no	= 0.0196	62	66	European	Toxicity	false		amisulpride; clozapine; olanzapine; quetiapine; risperidone
1451550253	rs2535764	PMCID:PMC7005197	RELN	Allele T is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele C.	no	= 0.179	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1450815058	rs17742120	PMCID:PMC3922978	PDE4D	Allele G is associated with increased response to quetiapine in people with Schizophrenia as compared to allele A.	yes	= 1.58E-07	160		Multiple groups, European American, African American and 'Other' ethnicities.	Efficacy	false	The number of G alleles present in a patient was negatively associated with PGI score. Please note that this variant is in high linkage disequilibrium with rs17382202 and rs2164660.	quetiapine
1183629344	rs1806201	PMID:23859574	GRIN2B	Genotype AA is associated with increased neurological adverse reactions when treated with quetiapine in healthy individuals as compared to genotypes AG + GG.	not stated	= 0.051	79		European	Toxicity	false	Alleles have been complemented to the plus chromosomal strand. Statistics did not mention correction for multiple testing. Statistics did not mention correction for multiple testing.	quetiapine
1448255358	rs1414334	PMCID:PMC4941738	HTR2C	Allele C is not associated with risk of Metabolic Syndrome when treated with amisulpride, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone or ziprasidone in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to allele G.	no	= 0.164	68	98	European	Toxicity	false	Because HTR2C is on the X chromosome, men and women were analyzed separately.	amisulpride; aripiprazole; clozapine; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone
981238738	rs35793	PMCID:PMC3518380	KCNMA1	Allele G is associated with response to quetiapine in people with Schizophrenia.	yes	= 1.81E-4	94		European	Efficacy	false	as measured by changes in PANSS-T (positive and negative syndrome scale total score), using a mixed model repeated measures approach. Examined 6789 SNPs - p-value of p< or equal to 5x10-4 was considered significant. Please note: reported allele was C, this has been complemented to the plus chromosomal strand. It was unclear whether the allele was associated with an increased or decreased response to drug.	quetiapine
1183699235	rs1128503	PMID:24240480	ABCB1	Allele A is not associated with differences pharmacokinetic parameters when treated with quetiapine in healthy individuals as compared to allele G.	no	> 0.05	40		East Asian	Metabolism/PK	false		quetiapine
1183491237	rs11960832	PMCID:PMC3845218	SV2C	Genotype TT is not associated with response to quetiapine in people with Schizophrenia as compared to genotypes CC + CT.	no	= 0.996	124		European	Efficacy	false	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	quetiapine
1184136868	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:23859574	SLC6A4	SLC6A4 HTTLPR long form (L allele) is associated with increased risk of Dizziness when treated with olanzapine, quetiapine or risperidone in healthy individuals as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	yes	= 0.015	206		European	Toxicity	false	The long allele was associated with increased likelihood of dizziness compared to patients with the short/short genotype. P value <0.05 for Chi-Squared analysis for this association. Statistics given below are for multivariate analysis for factors contributing to headache. The article used the SLC6A4 rs4795541 [5HTTLPR L/S] for identification. Historically a long insertion/deletion was submitted under this SNP. Currently, the rsnumber does not support a long insertion/deletion on dbSNP.	olanzapine; quetiapine; risperidone
1448998892	rs7799039	PMID:20504252	LEP	Genotype GG is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AA + AG.	no	= 0.0196	62	66	European	Toxicity	false		amisulpride; clozapine; olanzapine; quetiapine; risperidone
1447679482	rs723672	PMID:26049408	CACNA1C	Allele C is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.16	176		East Asian	Efficacy	false	Study looked at association of genotype and alleles in response to antipsychotics, using 4 PANSS scales (Positive and Negative Syndrome Scale): PANSS total, PANSS positive, PANSS negative, PANSS general. Patients were on one of the following drugs: risperidone, olanzapine, quetiapine.	olanzapine; quetiapine; risperidone
655388451	rs1414334	PMID:20680028	HTR2C	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics, aripiprazole, clozapine, olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele G.	yes	= 0.015	186		European	Toxicity	false	Note: this is an x-linked gene on plus strand. Male subjects have only one copy of the allele (C or G) whereas female subjects can be CC, CG or GG.	antipsychotics; aripiprazole; clozapine; olanzapine; quetiapine; risperidone
1451550259	rs12705169	PMCID:PMC7005197	RELN	Allele G is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.596	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1448998884	rs3813929	PMID:20504252	HTR2C	Genotype CC is associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CT + TT.	yes	= 0.04	62	66	European	Toxicity	false	Groups compared were CC females plus C males vs CT females + TT females + T males. (gene is x-linked).	amisulpride; clozapine; olanzapine; quetiapine; risperidone
1183699255	rs776746	PMID:24240480	CYP3A5	Genotype CC is associated with decreased metabolism of quetiapine in healthy individuals as compared to genotypes CT + TT.	yes	= 0.0002	40		East Asian	Metabolism/PK	false		quetiapine
1447520509	rs6280	PMID:25025989	DRD3	Genotype TT is associated with increased clearance of quetiapine in healthy individuals as compared to genotypes CC + CT.	yes	= 0.012	79		European	Metabolism/PK	false	Text describes this comparison as Ser/Ser versus Gly. The rs number is the most commonly discussed in DRD3	quetiapine
1447987701	rs1415744	PMID:27092952	EPM2A	Allele C is associated with increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone or trifluoperazine in people with Schizophrenia as compared to allele T.	yes	= 0.02	573		East Asian	Efficacy	false	Symptom improvement measured by PANSS score (Positive and Negative Symptom Scale) after 20-40 days of treatment. The CC genotype was associated with an improved response compared to CT, which was also associated with an improved response compared to TT. The CG haplotype of rs1415744 and rs702304 was associated with improvement on the negative symptom scale (p=0.02).	chlorpromazine; clozapine; haloperidol; olanzapine; quetiapine; risperidone; trifluoperazine
1451550271	rs362626	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele A.	no	= 0.394	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1450815045	rs17382202	PMCID:PMC3922978	PDE4D	Allele T is associated with increased response to quetiapine in people with Schizophrenia as compared to allele C.	yes	= 4.21E-08	160		Multiple groups, European American, African American and 'Other' ethnicities.	Efficacy	false	The number of T alleles present in a patient was negatively associated with PGI score. Please note that this variant is in high linkage disequilibrium with rs17742120 and rs2164660.	quetiapine
1451550265	rs2237628	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.160	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1447679991	rs2283271	PMID:26049408	CACNA1C	Allele A is not associated with response to olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.07	176		East Asian	Efficacy	false	Study looked at association of genotype and alleles in response to antipsychotics, using 4 PANSS scales (Positive and Negative Syndrome Scale): PANSS total, PANSS positive, PANSS negative, PANSS general. Patients were on one of the following drugs: risperidone, olanzapine, quetiapine.	olanzapine; quetiapine; risperidone
1446898434	rs12970134	PMCID:PMC4166499		Allele A is not associated with increased risk of Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to allele G.	no	= 3.26E-6	139		Unknown	Other	true		amisulpride; aripiprazole; clozapine; haloperidol; quetiapine; risperidone; ziprasidone
1447520517	CYP2C19*1; CYP2C19*2; CYP2C19*4	PMID:25025989	CYP2C19	CYP2C19 *1/*2 + *2/*2 + *2/*4 are associated with increased severity of Hyperprolactinemia when treated with quetiapine in healthy individuals as compared to CYP2C19 *1/*1.	yes	< 0.05	79		European	Metabolism/PK	false		quetiapine
1451648462	CYP3A4*1; CYP3A4*22	PMID:24525658	CYP3A4	CYP3A4 *1/*22 + *22/*22 is associated with increased concentrations of quetiapine in people with Psychotic Disorders as compared to CYP3A4 *1/*1.	yes	= 0.01	238		Unknown	Metabolism/PK	false		quetiapine
1446898423	rs646749	PMCID:PMC4166499		Allele A is not associated with increased risk of Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to allele G.	no	= 3.09E-7	139		Unknown	Other	true		amisulpride; aripiprazole; clozapine; haloperidol; quetiapine; risperidone; ziprasidone
1451550286	rs362813	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.903	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1448998934	rs6318	PMID:20504252	HTR2C	Genotype GG is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CC + CG.	no	= 0.0196	62	66	European	Toxicity	false	Groups compared were GG females plus G males vs CG females + CC females + C males. (gene is x-linked).	amisulpride; clozapine; olanzapine; quetiapine; risperidone
1451550280	rs362814	PMCID:PMC7005197	RELN	Allele A is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.973	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1451156401	rs1045642	PMID:17502774	ABCB1	Genotype AA is not associated with concentrations of quetiapine as compared to genotypes AG + GG.	no		14		European	Metabolism/PK	false	Study in patients receiving methadone maintenance therapy. No significant difference in plasma level-dose ratios of quetiapine between genotypes. Allele referred to in the paper as 3435C>T.	quetiapine
1451550292	rs362731	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.134	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1184469067	rs7912580	PMID:24751813		Genotype AG is associated with increased response to olanzapine, quetiapine, risperidone or ziprasidone in people with Schizophrenia as compared to genotype GG.	no	> 0.05	1406		Unknown	Efficacy	false	results did not reach significance.	olanzapine; quetiapine; risperidone; ziprasidone
1448998926	rs7566605	PMID:20504252	INSIG2	Genotype GG is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CC + CG.	no	= 0.0196	62	66	European	Toxicity	false		amisulpride; clozapine; olanzapine; quetiapine; risperidone
1446898411	rs489693	PMCID:PMC4166499	MC4R	Genotype AA is associated with increased likelihood of Hypertriglyceridemia and Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AC + CC.	yes	< 0.01	139		Unknown	Other	true		amisulpride; aripiprazole; clozapine; haloperidol; quetiapine; risperidone; ziprasidone
769261698	rs3813929	PMID:21121776	HTR2C	Allele C is associated with increased risk of Weight gain when treated with amisulpride, clozapine, haloperidol, iloperidone, olanzapine, quetiapine, risperidone and ziprasidone as compared to allele T.	yes	= 0.006			Multiple groups, Mostly European samples	Other	false	In this meta-analysis, statistical significance was gained when looking at mostly European populations. This gene is on the X chromosome, males on have one copy.	amisulpride; clozapine; haloperidol; iloperidone; olanzapine; quetiapine; risperidone; ziprasidone
1451550301	rs362726	PMCID:PMC7005197	RELN	Allele C is not associated with response to aripiprazole, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.	no	= 0.862	259		East Asian	Efficacy	false	Response was assessed by changes in PANSS score. A reduction of 50% or more in PANSS score was classified as a good response.	aripiprazole; olanzapine; perphenazine; quetiapine; risperidone
1448998918	rs17047764	PMID:20504252	INSIG2	Genotype GG is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CC + CG.	no	= 0.0196	62	66	European	Toxicity	false		amisulpride; clozapine; olanzapine; quetiapine; risperidone
1448632504	rs502046	PMCID:PMC2986499	RIMS1	Genotypes CC + CT is associated with decreased likelihood of discontinuation when treated with quetiapine in people with Schizophrenia as compared to genotype TT.	yes	= 0.021	82	47	Multiple groups	Efficacy,Toxicity	false		quetiapine
1446898393	rs489693	PMCID:PMC4166499	MC4R	Allele A is associated with increased risk of Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to allele C.	yes	= 5.59E-12	344		Multiple groups	Other	true		amisulpride; aripiprazole; clozapine; haloperidol; quetiapine; risperidone; ziprasidone
1449181828	rs1137101	PMID:29441581	LEPR; LEPROT	Genotype GG is not associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine, quetiapine or risperidone in people with Psychotic Disorders and Schizophrenia as compared to genotypes AA + AG.	no	= 0.816	64	136	East Asian	Toxicity	false	Most patients were on mono therapy (94%) risperidone or clozapine, 6% were on 2 drugs.	clozapine; olanzapine; quetiapine; risperidone
827828530	rs324420	PMID:20631561	FAAH	Allele A is associated with increased likelihood of Weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone in people with Psychotic Disorders as compared to allele C.	yes	= 0.002	83		European	Toxicity	false	weight gain of more than 7% of baseline body weight	aripiprazole; clozapine; haloperidol; olanzapine; quetiapine; risperidone
1448423731	rs4818	PMID:26282453	COMT	Allele C is associated with decreased response to quetiapine in people with Schizophrenia as compared to allele G.	yes	= 0.007	995		East Asian	Efficacy	false	This association was significant after Bonferroni correction. The C allele was frequently observed in poor responders to quetiapine. Patients were classified as good responders if they had a reduction of Positive and Negative Syndrome Scale (PANSS) score of >=50% and poor responders if they had a reduction of PANSS score of <50%.	quetiapine
1449731970	rs1045642	PMID:29723928	ABCB1	Genotype AA is not associated with exposure to quetiapine in healthy individuals as compared to genotypes AG + GG.	no	> 0.05	36		Unknown	Metabolism/PK	false	Please note that alleles have been complemented to the positive strand. Genotype at rs1045642 had no statistically significant association with AUC, Cmax, half-life, Tmax, Cl/F or Vd/F of quetiapine.	quetiapine
827828539	rs1049353	PMID:20631561	CNR1	Allele T is not associated with increased likelihood of Weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone in people with Psychotic Disorders as compared to allele C.	no	= 0.7	83		European	Toxicity	false	weight gain of more than 7% of baseline body weight	aripiprazole; clozapine; haloperidol; olanzapine; quetiapine; risperidone
1448639669	rs1799752	PMCID:PMC5600660	ACE	Allele del is not associated with Memory Disorders when exposed to aripiprazole, clozapine, olanzapine, quetiapine, risperidone or ziprasidone in people with Psychotic Disorders, schizoaffective disorder and Schizophrenia as compared to allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	no	> 0.05	122		Unknown	Other	false	Verbal memory and exploratory recall ratio performance analysis were significantly influenced by genetics BUT only in the low-education group. However, medication use (ACEI or ARB interacted with RAS risk alleles, statin interacted with APOE e 4 carrier status, or atypical vs typical antipsychotic use) was not associated with outcomes.	aripiprazole; clozapine; olanzapine; quetiapine; risperidone; ziprasidone
1451156368	CYP2B6*1; CYP2B6*5; CYP2B6*6; CYP2B6*7	PMID:17502774	CYP2B6	CYP2B6 *6/*6 is not associated with concentrations of quetiapine as compared to CYP2B6 *1/*1 + *1/*5 + *1/*6 + *1/*7.	no		14		European	Metabolism/PK	false	Study in patients receiving methadone maintenance therapy. No significant difference in plasma level-dose ratios of quetiapine between genotype groups. Patients were genotyped for the *4, *5, *6, *7 and *9 alleles, but no details on the specific variants assayed are given.	quetiapine
1446898383	rs17782313	PMID:23920449	MC4R	Genotype CC is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes CT + TT.	yes	= 0.005	173		Unknown	Other	false	The authors analyzed the whole population of all patients administered one of many anti-psychotics, then a subpopulation without additional weight gain-inducing co-medication (adjusted sub-population) (weight-gaining co-meds included TCA, mirtazapine, lithium, valproic acid, and paroxetine) as well as a sub-group of patients for whom anti-psychotics were given for a first episode. The authors calculated adjusted means for weight gain 4 wk post-initiation of medication using ANCOVA and rs17782313 genotype as a independent variable.	amisulpride; clozapine; olanzapine; paliperidone; quetiapine; risperidone
1448423713	rs6269	PMID:26282453	COMT	Allele A is associated with decreased response to quetiapine in people with Schizophrenia as compared to allele G.	yes	= 0.008	995		East Asian	Efficacy	false	This association was significant after Bonferroni correction. The A allele was frequently observed in poor responders quetiapine. Patients were classified as good responders if they had a reduction of Positive and Negative Syndrome Scale (PANSS) score of >=50% and poor responders if they had a reduction of PANSS score of <50%.	quetiapine
1451156360	CYP2D6*1; CYP2D6*3; CYP2D6*4	PMID:17502774	CYP2D6	CYP2D6 *3/*4 + *4/*4 are not associated with concentrations of quetiapine as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.	no		14		European	Metabolism/PK	false	Study in patients receiving methadone maintenance therapy. No significant difference in plasma level-dose ratios of quetiapine between genotype groups. Patients were genotyped for the *3, *4 and *6 alleles, but no details on the specific variants assayed are given.	quetiapine
1448423725	rs5993883	PMID:26282453	COMT	Allele T is associated with decreased response to quetiapine in people with Schizophrenia as compared to allele G.	yes	= 0.007	995		East Asian	Efficacy	false	This association was significant after Bonferroni correction. The T allele was frequently observed in poor responders to quetiapine. Patients were classified as good responders if they had a reduction of Positive and Negative Syndrome Scale (PANSS) score of >=50% and poor responders if they had a reduction of PANSS score of <50%.	quetiapine
982030065	CYP2D6*4; CYP2D6*6	PMID:16871470	CYP2D6	CYP2D6 *4/*6 is associated with increased risk of Drug Toxicity when treated with clomipramine and quetiapine in people with Depressive Disorder, Major.	not stated		1		European	Toxicity	false	Case report. Male with major depression experienced multiple adverse drug reaction during clomipramine and quetiapine (600-700mg/day) treatment. Patient was genotype as CYP2D6*4/*6 (PM) and phenotyped for CYP3A4/5 as having a low CYP3A4/5 activity. Clomipramine was given after trials with mitrazapine and venlafaxine. After 7 days of clomipramine treatment patient received 300mg/day. ADRs experienced were sweating, tachycardia, hypotension, dizziness, and constipation. Increased plasma concentrations of clomipramine + demethylclomipranine 1228 ng/ml (therapeutic range 175-400g/ml) and quetiapine 826ng/ml (range 70-170 ng/ml) were found. After discontinuation of quetiapine and decreasing the dose of clomipramine to 75 mg/day plasma level were found in the normal range and the ADR resolved.	clomipramine; quetiapine
1448998695	rs3813929	PMID:20680028	HTR2C	Allele T is not associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics, aripiprazole, clozapine, olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele C.	no		186		European	Toxicity	false	Note: this is an x-linked gene so male subjects have only one copy of the allele (T or C) whereas female subjects can be TT, CT or CC.	antipsychotics; aripiprazole; clozapine; olanzapine; quetiapine; risperidone
1184469093	rs2412459	PMID:24751813	EIF2AK4	Genotype CT is associated with increased response to olanzapine, quetiapine, risperidone or ziprasidone in people with Schizophrenia as compared to genotype TT.	no	> 0.05	1406		Unknown	Efficacy	false	results did not reach significance.	olanzapine; quetiapine; risperidone; ziprasidone
1448997283	rs680055	PMID:25150845	CYP3A43	Genotype CG is associated with increased response to antipsychotics, aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to genotype CC.	yes	= 0.013	152		European	Efficacy	false	No GG homozygotes were observed. Approximately 50% of patients were receiving clozapine, the rest had other antipsychotics including risperidone (N = 25), olanzapine (N = 16), haloperidol (N = 7), amisulpride (N = 6), aripiprazole (N = 15), ziprasidone (N = 1), fluphenazine (N = 1) and quetiapine (N = 5)	antipsychotics; aripiprazole; clozapine; haloperidol; olanzapine; quetiapine; risperidone
1451432060	rs1801133	PMID:33858192	MTHFR	Genotype AG is associated with decreased clinical benefit to antipsychotics, chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine or risperidone in women with Schizophrenia as compared to genotype GG.	yes	= 0.008	117		Near Eastern	Efficacy	false	"response is measured by PANSS (Positive and Negative Syndrome Scale), alleles complemented to plus chromosomal strand. In initial evaluation of whole cohort (men and women) authors stated ""A
significantly higher mean score was also found in those having MTHFR CT genotype compared with CC and TT
patients. "" ""Higher negative Positive and Negative Syndrome Scale scores were significantly associated with women and having the CT genotype for MTHFR c.677C>T (β = 4.25; p = 0.008) compared with CC patients. """	antipsychotics; chlorpromazine; clozapine; haloperidol; olanzapine; quetiapine; risperidone
